Item 5.07 Submission of Matters to a Vote of Security Holders.

4D Molecular Therapeutics, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting") on May 17, 2021 virtually via the internet. On March 26, 2021, the record date, there were 26,694,379 shares of the Company's common stock outstanding with each such share being entitled to one vote per share.

At the Annual Meeting, 16,717,561 shares of the Company's common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 6, 2021.



Proposal 1. The Company's stockholders elected by a majority of votes cast the
Class I director nominees below to the Company's Board of Directors to hold
office until the 2024 Annual Meeting of Stockholders or until their successors
are elected.



                                                          BROKER
                                                           NON-
NOMINEE                     FOR           WITHHELD         VOTES
David Kirn, M.D.          13,952,085       1,873,828       891,648
David Schaffer, Ph.D.     13,179,909       2,646,004       891,648

Proposal 2. The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.





    FOR          AGAINST      ABSTAIN
  16,698,132       18,996       433



                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses